Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Aluminium glycinate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Aluminium glycinate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Aluminium glycinate. |
| Dabigatran etexilate | Aluminium glycinate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Aluminium glycinate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Aluminium glycinate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Aluminium glycinate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Aluminium glycinate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Aluminium glycinate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Aluminium glycinate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Aluminium glycinate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Aluminium glycinate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Aluminium glycinate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Aluminium glycinate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | Aluminium glycinate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Aluminium glycinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Aluminium glycinate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium glycinate. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium glycinate. |
| Captopril | Aluminium glycinate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium glycinate. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium glycinate. |
| Chloroquine | Aluminium glycinate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Aluminium glycinate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gabapentin enacarbil | The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Aluminium glycinate. |
| Hyoscyamine | Aluminium glycinate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Aluminium glycinate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Aluminium glycinate may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Aluminium glycinate may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Aluminium glycinate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Aluminium glycinate may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Quinine | Aluminium glycinate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Aluminium glycinate. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Aluminium glycinate. |
| Deferasirox | Aluminium glycinate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Aluminium glycinate. |
| Fexofenadine | Aluminium glycinate can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Aluminium glycinate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Aluminium glycinate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mesalazine | Aluminium glycinate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Aluminium glycinate. |
| Ursodeoxycholic acid | Aluminium glycinate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Aluminium glycinate can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Aluminium glycinate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Aluminium glycinate can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Aluminium glycinate can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Aluminium glycinate can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Obeticholic acid | Aluminium glycinate can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Aluminium glycinate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Aluminium glycinate can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Aluminium glycinate can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Aluminium glycinate can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| cis-Diamminechlorocholylglycinateplatinum(II) | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium glycinate. |
| Dehydrocholic acid | Aluminium glycinate can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Aluminium glycinate can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aramchol | The serum concentration of Aramchol can be decreased when it is combined with Aluminium glycinate. |
| Ox bile extract | The serum concentration of Ox bile extract can be decreased when it is combined with Aluminium glycinate. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Aluminium glycinate. |
| Ketoconazole | Aluminium glycinate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiethylperazine | Aluminium glycinate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promazine | Aluminium glycinate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prochlorperazine | Aluminium glycinate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorpromazine | Aluminium glycinate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triflupromazine | Aluminium glycinate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluphenazine | Aluminium glycinate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioridazine | Aluminium glycinate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moricizine | Aluminium glycinate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trifluoperazine | Aluminium glycinate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine | Aluminium glycinate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mesoridazine | Aluminium glycinate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetophenazine | Aluminium glycinate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Aluminium glycinate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alimemazine | Aluminium glycinate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrimeprazine | Aluminium glycinate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Periciazine | Aluminium glycinate can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acepromazine | Aluminium glycinate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aceprometazine | Aluminium glycinate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipotiazine | Aluminium glycinate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioproperazine | Aluminium glycinate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| BL-1020 | Aluminium glycinate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cyamemazine | Aluminium glycinate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylene blue | Aluminium glycinate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propiopromazine | Aluminium glycinate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perazine | Aluminium glycinate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Butaperazine | Aluminium glycinate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorproethazine | Aluminium glycinate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiazinam | Aluminium glycinate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dixyrazine | Aluminium glycinate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine enanthate | Aluminium glycinate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminium glycinate. |
| Doxycycline | Aluminium glycinate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lymecycline | Aluminium glycinate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clomocycline | Aluminium glycinate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxytetracycline | Aluminium glycinate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demeclocycline | Aluminium glycinate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetracycline | Aluminium glycinate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metacycline | Aluminium glycinate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Minocycline | Aluminium glycinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarecycline | Aluminium glycinate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omadacycline | Aluminium glycinate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |